Sirius Therapeutics, a clinical-stage biotech company specializing in small interfering RNA (siRNA) therapies, has entered into a strategic partnership with CRISPR Therapeutics. The collaboration aims to develop and commercialize siRNA therapies for global markets. Under the agreement’s terms, CRISPR Therapeutics will provide an upfront payment of $25 million in cash and $70 million in equity to Sirius.
Cooley LLP advised Sirius on this deal. The legal team included Alan Tamarelli, Jiqiang Lin, Navya Dasari, Aaron Pomeroy, Todd Gluth, Rick Jantz, Steve Przesmicki, Robert Eisenbach, Rachel Thorn, and David Burns.
Cooley LLP is known for its involvement in transformative deals and complex intellectual property matters. The firm employs nearly 1,400 lawyers across 19 offices worldwide.
The information provided here is for general informational purposes only and does not establish an attorney-client relationship with Cooley LLP or any affiliated entities. Readers are advised to seek professional legal advice tailored to their circumstances.
